Centipeda minima active components and mechanisms in lung cancer
Abstract Background Traditional Chinese medicine (TCM) has been extensively used for neoplasm treatment and has provided many promising therapeutic candidates. We previously found that Centipeda minima (C. minima), a Chinese medicinal herb, showed anti-cancer effects in lung cancer. However, the act...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | BMC Complementary Medicine and Therapies |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12906-023-03915-y |
| _version_ | 1797860016932257792 |
|---|---|
| author | Cuiyun Gao Huafeng Pan Fengjun Ma Ze Zhang Zedan Zhao Jialing Song Wei Li Xiangzhen Fan |
| author_facet | Cuiyun Gao Huafeng Pan Fengjun Ma Ze Zhang Zedan Zhao Jialing Song Wei Li Xiangzhen Fan |
| author_sort | Cuiyun Gao |
| collection | DOAJ |
| description | Abstract Background Traditional Chinese medicine (TCM) has been extensively used for neoplasm treatment and has provided many promising therapeutic candidates. We previously found that Centipeda minima (C. minima), a Chinese medicinal herb, showed anti-cancer effects in lung cancer. However, the active components and underlying mechanisms remain unclear. In this study, we used network pharmacology to evaluate C. minima active compounds and molecular mechanisms in lung cancer. Methods We screened the TCMSP database for bioactive compounds and their corresponding potential targets. Lung cancer-associated targets were collected from Genecards, OMIM, and Drugbank databases. We then established a drug-ingredients-gene symbols-disease (D-I-G-D) network and a protein–protein interaction (PPI) network using Cytoscape software, and we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses using R software. To verify the network pharmacology results, we then performed survival analysis, molecular docking analysis, as well as in vitro and in vivo experiments. Results We identified a total of 21 C. minima bioactive compounds and 179 corresponding targets. We screened 804 targets related to lung cancer, 60 of which overlapped with C. minima. The top three candidate ingredients identified by D-I-G-D network analysis were quercetin, nobiletin, and beta-sitosterol. PPI network and core target analyses suggested that TP53, AKT1, and MYC are potential therapeutic targets. Moreover, molecular docking analysis confirmed that quercetin, nobiletin, and beta-sitosterol, combined well with TP53, AKT1, and MYC respectively. In vitro experiments verified that quercetin induced non-small cell lung cancer (NSCLC) cell death in a dose-dependent manner. GO and KEGG analyses found 1771 enriched GO terms and 144 enriched KEGG pathways, including a variety of cancer related pathways, the IL-17 signaling pathway, the platinum drug resistance pathway, and apoptosis pathways. Our in vivo experimental results confirmed that a C. minima ethanol extract (ECM) enhanced cisplatin (CDDP) induced cell apoptosis in NSCLC xenografts. Conclusions This study revealed the key C. minima active ingredients and molecular mechanisms in the treatment of lung cancer, providing a molecular basis for further C. minima therapeutic investigation. |
| first_indexed | 2024-04-09T21:38:54Z |
| format | Article |
| id | doaj.art-4e4aeee1e495413b8d5e704520c5708f |
| institution | Directory Open Access Journal |
| issn | 2662-7671 |
| language | English |
| last_indexed | 2024-04-09T21:38:54Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Complementary Medicine and Therapies |
| spelling | doaj.art-4e4aeee1e495413b8d5e704520c5708f2023-03-26T11:06:39ZengBMCBMC Complementary Medicine and Therapies2662-76712023-03-0123112010.1186/s12906-023-03915-yCentipeda minima active components and mechanisms in lung cancerCuiyun Gao0Huafeng Pan1Fengjun Ma2Ze Zhang3Zedan Zhao4Jialing Song5Wei Li6Xiangzhen Fan7Department of Rehabilitation Medicine, Binzhou Medical University HospitalScience and Technology Innovation Center, Guangzhou University of Chinese MedicineShandong University of Traditional Chinese MedicineSchool of Rehabilitation Medicine, Binzhou Medical UniversitySchool of Rehabilitation Medicine, Binzhou Medical UniversitySchool of Rehabilitation Medicine, Binzhou Medical UniversityDepartment of Rehabilitation Medicine, Binzhou Medical University HospitalDepartment of Rehabilitation Medicine, Binzhou Medical University HospitalAbstract Background Traditional Chinese medicine (TCM) has been extensively used for neoplasm treatment and has provided many promising therapeutic candidates. We previously found that Centipeda minima (C. minima), a Chinese medicinal herb, showed anti-cancer effects in lung cancer. However, the active components and underlying mechanisms remain unclear. In this study, we used network pharmacology to evaluate C. minima active compounds and molecular mechanisms in lung cancer. Methods We screened the TCMSP database for bioactive compounds and their corresponding potential targets. Lung cancer-associated targets were collected from Genecards, OMIM, and Drugbank databases. We then established a drug-ingredients-gene symbols-disease (D-I-G-D) network and a protein–protein interaction (PPI) network using Cytoscape software, and we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses using R software. To verify the network pharmacology results, we then performed survival analysis, molecular docking analysis, as well as in vitro and in vivo experiments. Results We identified a total of 21 C. minima bioactive compounds and 179 corresponding targets. We screened 804 targets related to lung cancer, 60 of which overlapped with C. minima. The top three candidate ingredients identified by D-I-G-D network analysis were quercetin, nobiletin, and beta-sitosterol. PPI network and core target analyses suggested that TP53, AKT1, and MYC are potential therapeutic targets. Moreover, molecular docking analysis confirmed that quercetin, nobiletin, and beta-sitosterol, combined well with TP53, AKT1, and MYC respectively. In vitro experiments verified that quercetin induced non-small cell lung cancer (NSCLC) cell death in a dose-dependent manner. GO and KEGG analyses found 1771 enriched GO terms and 144 enriched KEGG pathways, including a variety of cancer related pathways, the IL-17 signaling pathway, the platinum drug resistance pathway, and apoptosis pathways. Our in vivo experimental results confirmed that a C. minima ethanol extract (ECM) enhanced cisplatin (CDDP) induced cell apoptosis in NSCLC xenografts. Conclusions This study revealed the key C. minima active ingredients and molecular mechanisms in the treatment of lung cancer, providing a molecular basis for further C. minima therapeutic investigation.https://doi.org/10.1186/s12906-023-03915-yCentipeda minimaLung cancerNetwork pharmacologyMolecular dockingExperimental validationMolecular mechanism |
| spellingShingle | Cuiyun Gao Huafeng Pan Fengjun Ma Ze Zhang Zedan Zhao Jialing Song Wei Li Xiangzhen Fan Centipeda minima active components and mechanisms in lung cancer BMC Complementary Medicine and Therapies Centipeda minima Lung cancer Network pharmacology Molecular docking Experimental validation Molecular mechanism |
| title | Centipeda minima active components and mechanisms in lung cancer |
| title_full | Centipeda minima active components and mechanisms in lung cancer |
| title_fullStr | Centipeda minima active components and mechanisms in lung cancer |
| title_full_unstemmed | Centipeda minima active components and mechanisms in lung cancer |
| title_short | Centipeda minima active components and mechanisms in lung cancer |
| title_sort | centipeda minima active components and mechanisms in lung cancer |
| topic | Centipeda minima Lung cancer Network pharmacology Molecular docking Experimental validation Molecular mechanism |
| url | https://doi.org/10.1186/s12906-023-03915-y |
| work_keys_str_mv | AT cuiyungao centipedaminimaactivecomponentsandmechanismsinlungcancer AT huafengpan centipedaminimaactivecomponentsandmechanismsinlungcancer AT fengjunma centipedaminimaactivecomponentsandmechanismsinlungcancer AT zezhang centipedaminimaactivecomponentsandmechanismsinlungcancer AT zedanzhao centipedaminimaactivecomponentsandmechanismsinlungcancer AT jialingsong centipedaminimaactivecomponentsandmechanismsinlungcancer AT weili centipedaminimaactivecomponentsandmechanismsinlungcancer AT xiangzhenfan centipedaminimaactivecomponentsandmechanismsinlungcancer |